Buckeyes

Great posts to Koo and myself- you nailed it!--

"No urgency though from anyone (DM, insiders, BP's, capital sources, China connections, etc), to move the needle after a vnarrow miss in BoM, a BTD, safety, and incredible ad hoc data from BoM suggesting immense potential with a redesigned and refined BoM2. And Hepa has already pledged 50% of the cost .... and crickets?

Mind boggling, from every angle and perspective."

Mind boggling it is - Resverlogix's last press release was 9-28 to confirm that apabetalone's future development would focus on treatment of Post Covid-19 conditions. BoM2 and BTD status  tabled for the time being. Since then - not a peep - hopefully  "the shroud of due diligence"

Time for some good news!